AstraZeneca, Merck secure FDA breakthrough therapy status for selumetinib
The designation has been provided based on Phase II data from the Sprint trial, which evaluated selumetinib as an oral monotherapy in pediatric patients aged three years or
ENCell has entered into a strategic alliance and licencing agreement with Lucy Biotech for EN001, a next-generation mesenchymal stem cell therapy.
In September 2018 the European Commission granted marketing authorization for NERLYNX (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast
TUDORZA PRESSAIR is indicated for the maintenance treatment of patients with COPD. According to Kenneth Chapman, MD, Clinical Researcher, Krembil Research Institute, University Health Network, University of Toronto,
The CHMP recommended approval of an expanded indication of REVLIMID as combination therapy with bortezomib and dexamethasone (RVd) for the treatment of adult patients with previously untreated multiple